MLN9708 Regimen Effective With Reduced Neuropathy Risk in Multiple Myeloma

ATLANTA (IMNG) - Of 65 patients with newly diagnosed multiple myeloma, nearly all had a partial or better response to an all-oral regimen containing the experimental proteasome inhibitor MLN9708.In the...
Source: OncologySTAT Latest News - Category: Cancer & Oncology Source Type: news